Adimab is a technology company.
Adimab is a biopharma company specializing in therapeutic antibody discovery and engineering, utilizing a proprietary yeast-based platform to deliver high-quality therapeutic candidates.
Adimab has raised $35.0M across 5 funding rounds.
Adimab has raised $35.0M in total across 5 funding rounds.
Adimab is a biotechnology company specializing in antibody discovery and protein engineering, using a proprietary yeast-based platform to develop fully human monoclonal antibodies, bispecific antibodies, and T cell engagers for therapeutic applications.[1][2][3][5] It serves pharmaceutical companies, biotech firms, and academic institutions by providing high-quality therapeutic leads through collaborations, having completed over 600 discovery campaigns and advanced more than 80 programs to clinical stages with over 135 partners.[2][5] This solves key challenges in biologics R&D by delivering diverse, developable antibodies with superior affinity, epitope coverage, and manufacturability faster than traditional methods, fueling an extensive industry pipeline.[3][4]
Founded in 2007 and headquartered in Lebanon, New Hampshire, Adimab employs 162 people and generated $23 million in revenue in 2024, backed by $32 million in funding from investors like Polaris Partners and OrbiMed.[5][6]
Adimab was founded in 2007 by Tillman U. Gerngross, who serves as CEO, with early funding from Series A rounds totaling around $6.3 million and a Series B of $3.18 million shortly after.[1][6] Gerngross, a serial entrepreneur with a background in biotechnology investments and analysis, aimed to revolutionize antibody discovery by bringing full-length IgG development into a controllable eukaryotic yeast system, merging in vitro speed with high-quality output.[3][4][6] Early traction came from its integrated platform's ability to rapidly produce purified, full-length human IgGs meeting stringent standards for affinity and expressability, attracting partners and leading to Polaris Venture Partners' board involvement via Terry McGuire.[4][6] Over 15+ years, this evolved into a collaborative model with dozens of programs reaching clinical development.[3]
Adimab stands out in the crowded antibody discovery field through these key strengths:
Adimab rides the wave of biologics innovation, particularly the surge in multispecific antibodies and protein therapeutics amid rising demand for targeted treatments in oncology, immunology, and autoimmune diseases.[1][3] Its timing aligns with post-2020 accelerations in biopharma R&D, where speed from target to clinic is critical amid patent cliffs and complex disease challenges, enabling partners to expand pipelines efficiently.[2][3] Market forces like AI integration in drug discovery and the need for scalable, high-quality antibodies favor Adimab's platform, which influences the ecosystem by advancing 600+ programs and fostering open innovation.[3][5] Competitors like AbCellera and AnaptysBio trail in campaign volume and clinical progress, underscoring Adimab's pivotal role in democratizing access to superior biologics tools.[5]
Adimab's momentum—bolstered by its massive partner network and clinical pipeline—positions it to dominate next-gen modalities like CAR-T engagers and novel multispecifics as protein engineering converges with AI and computation.[3][5] Trends like personalized medicine and immune-oncology will amplify demand, potentially driving more platform transfers and in-house advancements. Its influence may evolve toward deeper biopharma integrations or IPO pursuits, solidifying leadership in transformative therapeutics that started with a bold yeast platform reimagining antibody discovery.[2][3][6]
Adimab has raised $35.0M in total across 5 funding rounds.
Adimab's investors include DFJ, Endeavor Venture Funds, G2VP, InterWest, Robert Garland, Polaris Partners, Section 32, UP.Partners, OrbiMed.
Adimab has raised $35.0M across 5 funding rounds. Most recently, it raised $14.0M Series F in April 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2012 | $14.0M Series F | DFJ, Endeavor Venture Funds, G2VP, InterWest, Robert Garland, Polaris Partners, Section 32, UP.Partners | |
| Jan 1, 2010 | $8.0M Series D | DFJ, Endeavor Venture Funds, G2VP, InterWest, Robert Garland, OrbiMed, Polaris Partners, Section 32, UP.Partners | |
| Nov 1, 2008 | $4.0M Series C | Endeavor Venture Funds, InterWest, Robert Garland, OrbiMed, Polaris Partners | |
| Mar 1, 2008 | $3.0M Series B | Endeavor Venture Funds, InterWest, Robert Garland, Polaris Partners | |
| Jul 1, 2007 | $6.0M Series A | Endeavor Venture Funds, InterWest, Robert Garland, Polaris Partners |